Navigation Links
EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical
Date:7/6/2010

OXFORD, England and LANGHORNE, Pennsylvania, July 6, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan. Under the terms of the companies' agreement, Ohara will be responsible for any late-stage development required by the Japanese authorities, and will pay EUSA an upfront fee and royalties on future sales.

Erwinase is an L-asparaginase derived from Erwinia chrysanthemi, which is used to treat acute lymphoblastic leukemia in combination with other anti-neoplastic agents. It is currently approved for use in Canada and in a number of countries in Europe, the Middle East and Asia, and is undergoing registration procedures in several other territories.

"This agreement represents an important strategic milestone for EUSA as it extends the reach of our partnership network to the Japanese market for the first time," said Bryan Morton, EUSA Pharma's President and Chief Executive Officer. "In the past four years EUSA has made great progress building a broad portfolio of marketed products and a specialty commercial infrastructure in Europe and North America. At the same time we have put in place a wider distribution network to bring our products to patients in over 80 countries around the world. Our n
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... DIEGO, June 7, 2011 Tocagen Inc. ... high grade glioma, such as those with glioblastoma multiforme ... Toca 511. The multicenter, open-label study is ... of Toca 511 administered intratumorally followed by cycles of ...
... 2011 Topaz Pharmaceuticals Inc., a privately held specialty ... Drug Administration (FDA) accepted for filing the New Drug ... as a treatment for head lice infestations in children ... transition of the Company from the development phase as ...
Cached Medicine Technology:Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... September 30, 2014 Keystone Symposia will convene ... first in its 2014-15 Global Health Series on ... Sheraton Seattle Hotel immediately following the conclusion of ... four-day conference is part of the Keystone Symposia Global ... Foundation, which has also funded travel awards for 36 ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... that some of them are literally ready to dive in ... spa on Saturday opened special baths meant to resemble ramen, ... giant pair of chopsticks overhead and water the aroma of ... have the effects of refreshing your mind, warming your burned-out ...
... Bush seems determined to hang on to his less-and-less-government stance ... veto a bipartisan plan to expand the Childrens Health Insurance ... with the Democratic majority in Congress, with a substantial number ... who want to expand the popular program to cover some ...
... of people reported sick after consuming food at the Chicago ... Cove Persian Cuisine booth at the Taste of Chicago ... July 2. ,Many people were sent to the hospital, ... from salmonella heidelberg bacteria. Tim Hadac, of the Chicago Health ...
... number of doctors in Portugal were refusing to carry out ... the 10th week of pregnancy . ,The law ... at least nine public hospitals out of a total of ... approved the law in March after a February referendum found ...
... southern China, after traders there capitalised on an outbreak of ... press reports ,According to a report Saturday in ... seen arriving late at night and sold to a wild ... ,During the SARS epidemic, which began in southern China in ...
... course at Promises and is officially out of rehab ... the actress has completed her 45-days rehab stint which ... will now be attending an intensive outpatient program. ... completed her 45 days of residential and extended care ...
Cached Medicine News:Health News:President Bush Not for Expansion of Child Health Insurance 2Health News:Food Poisoning at the Chicago Food Festival 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: